BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 21273557)

  • 1. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
    Roubtsova A; Munkonda MN; Awan Z; Marcinkiewicz J; Chamberland A; Lazure C; Cianflone K; Seidah NG; Prat A
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):785-91. PubMed ID: 21273557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
    Demers A; Samami S; Lauzier B; Des Rosiers C; Ngo Sock ET; Ong H; Mayer G
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2517-25. PubMed ID: 26494228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.
    Roubtsova A; Chamberland A; Marcinkiewicz J; Essalmani R; Fazel A; Bergeron JJ; Seidah NG; Prat A
    J Lipid Res; 2015 Nov; 56(11):2133-42. PubMed ID: 26323289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
    Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
    J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
    Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
    Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
    Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
    Denis M; Marcinkiewicz J; Zaid A; Gauthier D; Poirier S; Lazure C; Seidah NG; Prat A
    Circulation; 2012 Feb; 125(7):894-901. PubMed ID: 22261195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
    Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
    Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
    Maxwell KN; Breslow JL
    Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
    Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
    Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
    Maxwell KN; Fisher EA; Breslow JL
    Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2069-74. PubMed ID: 15677715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
    Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
    Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.